|
John W. Newcomer, M.D., was awarded a $2.1 million contract to study the effectiveness of an injectable long-acting antipsychotic medication in individuals with schizophrenia.
The contract with Otsuka America Pharmaceutical Inc. will last two years. During that time, investigators from
 FAU and collaborators that include faculty at the Washington University in St. Louis School of Medicine will evaluate hospitalization rates and metabolic measurements during treatment with long-acting injectable aripiprazole, compared with daily oral antipsychotic treatment in the six months following an inpatient hospital stay related to schizophrenia. "This research is important because the availability of second-generation long-acting antipsychotic medications offers an important tool to assist patients with medication adherence, which in turn may help lower health care costs and improve quality of life," said Newcomer. | 
In his new roles, he will work in two key areas: To build a clinical research infrastructure that will rapidly test new therapies and accelerate these innovations to market; and to create a novel clinical component that will develop new, comprehensive approaches of care for people with Alzheimer's disease and dementia and their families to improve their quality of life.
podiatrist's office next door had a heart attack. Patients from the podiatrist's office rushed into the internist's office for help. Coby immediately took action, performing life-saving CPR on the patient before the ambulance arrived! "We are all so proud of Coby," said Dr. Breuer and Dr. Lizotte-Waniewski, who witnessed Coby's heroic effort.